StockNews.AI
ACON
StockNews.AI
166 days

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

1. Aclarion plans to expand Nociscan access in New York and New Jersey. 2. New sites aim to increase scan volumes due to physician demand. 3. Nociscan identified with a 97% surgical success rate for pain treatment. 4. Chronic low back pain affects 266 million people globally, validating market need. 5. Strong relationship with RadNet enhances market penetration for Aclarion.

7m saved
Insight
Article

FAQ

Why Bullish?

The expansion of Nociscan indicates growing demand and potential revenue increase. Historically, similar expansions have resulted in stock price boosts.

How important is it?

The article highlights significant expansion and partnerships that can enhance ACON's market position.

Why Long Term?

The long-term impact is supported by market expansion plans and growing chronic pain prevalence.

Related Companies

RADMRKMDT
BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet affiliates in both states and are driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan. “Expanding scanner access is a key element of our strategy to drive Nociscan to standard of care for patients with chronic low back pain,” said Brent Ness, Chief Executive Officer of Aclarion. “The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this important national imaging provider.” Lenox Hill Radiology (LHR) operates convenient, outpatient imaging centers located in the metropolitan New York area, and 79 total locations throughout New York state. LHR Park Avenue, a flagship site, initially adopted Nociscan to provide access to leading spine physicians in private practice and from globally recognized organizations such as Weill Cornell. New Jersey Imaging Network (NJIN) is one of the largest imaging providers in NJ with 33 locations. NJIN-Union, in metro NJ, was the first site in NJ to adopt Nociscan to support both local physicians and out-of-market referrals through the convenience of Newark Liberty International Airport and Teterboro Airport. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated. To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@aclarion.com About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com Media Contact: Jennie KimSPRIG Consultingjennie@sprigconsulting.com

Related News